| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 11/17/2005 | WO2005109313A2 Enclosing drugs with synthetic oligonucleotides |
| 11/17/2005 | WO2005108396A1 Therapeutic agent for keratoconjunctiva disorder |
| 11/17/2005 | WO2005107846A2 Packaging for a therapeutic agent, consisting of a covering film, a non-woven film, and a therapeutic agent layer |
| 11/17/2005 | WO2005107820A1 Compositions and methods for enhancing contrast in imaging |
| 11/17/2005 | WO2005107813A1 Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative |
| 11/17/2005 | WO2005107812A1 Permeation enhancing compositions for anticholinergic agents |
| 11/17/2005 | WO2005107811A2 Drug delivery device |
| 11/17/2005 | WO2005107788A1 Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| 11/17/2005 | WO2005107776A1 METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
| 11/17/2005 | WO2005107774A1 Pharmaceutical wound healing composition |
| 11/17/2005 | WO2005107765A2 Heart treatment method |
| 11/17/2005 | WO2005107764A1 Perfluorocarbon-soluble compounds |
| 11/17/2005 | WO2005107761A1 Sustained-release oral molsidomine composition for treating atherosclerosis |
| 11/17/2005 | WO2005107759A1 Bh4-responsive hyperphenylalaninemia remedies |
| 11/17/2005 | WO2005107753A2 Naltrexone long acting formulations and methods of use |
| 11/17/2005 | WO2005107750A1 Controlled release metformin compositions |
| 11/17/2005 | WO2005107733A1 Dermatological external preparation for local anesthesia |
| 11/17/2005 | WO2005107732A1 Topical preparation containing ambroxol |
| 11/17/2005 | WO2005107728A2 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 11/17/2005 | WO2005107727A1 Steroid intraocular implants having an extended sustained release for a period of greater than two months |
| 11/17/2005 | WO2005107723A2 Transdermal delivery systems and transdermal chelation preparations |
| 11/17/2005 | WO2005107722A2 Directly compressible tricalcium phosphate |
| 11/17/2005 | WO2005107721A2 Pharmaceutical dosage form comprising pellets as well as its manufacturing process |
| 11/17/2005 | WO2005107720A2 Sealed capsule including and integrated puncturing mechanism |
| 11/17/2005 | WO2005107719A2 Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| 11/17/2005 | WO2005107718A1 Anti-excitotoxic sustained release intraocular implants and related methods |
| 11/17/2005 | WO2005107717A2 Oral dosage form for the extended release of biguanide and sulfonylurea |
| 11/17/2005 | WO2005107716A1 Controlled release paroxetine-containing tablets based on a core and a coating |
| 11/17/2005 | WO2005107715A1 Implantable composition |
| 11/17/2005 | WO2005107714A2 Method of forming microparticles that include a bisphosphonate and a polymer |
| 11/17/2005 | WO2005107713A2 Swellable dosage form comprising gellan gum |
| 11/17/2005 | WO2005107712A1 Liposomes useful for drug delivery |
| 11/17/2005 | WO2005107711A2 Method and composition for treating rhinitis |
| 11/17/2005 | WO2005107710A2 Particles for the delivery of active agents |
| 11/17/2005 | WO2005107709A2 Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients |
| 11/17/2005 | WO2005107708A1 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 11/17/2005 | WO2005107707A1 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| 11/17/2005 | WO2005107706A2 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 11/17/2005 | WO2005107705A2 Extended therapeutic effect ocular implant treatments |
| 11/17/2005 | WO2005107704A1 A system and a method for starch-based, slow-release oral dosage forms |
| 11/17/2005 | WO2005107703A1 Novel pharmaceutical formulation of cefixime for enhanced bioavailability |
| 11/17/2005 | WO2005107702A2 Sustained release, mucoadhesive vaginal pharmaceutical compositions |
| 11/17/2005 | WO2005107701A2 Remote control release of material encapsulated in polyelectrolyte multilayer microcapsules |
| 11/17/2005 | WO2005107699A1 Foamed cleanser with suspended particles, a method of producing same, and a dispenser therefore |
| 11/17/2005 | WO2005107679A2 Protective microcontainers |
| 11/17/2005 | WO2005107660A1 Condom with a coating and composition |
| 11/17/2005 | WO2005094385A3 Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol |
| 11/17/2005 | WO2005084639A9 Polymeric drug delivery system for hydrophobic drugs |
| 11/17/2005 | WO2005082337A3 Compositions comprising prodrugs of proton pump inhibitors |
| 11/17/2005 | WO2005082048A3 Dissolvable film and method of manufacture |
| 11/17/2005 | WO2005058356A3 Methods for porducing storage stable viruses and immunogenic compositions thereof |
| 11/17/2005 | WO2005058275A3 Ingestible capsules containing ethanol |
| 11/17/2005 | WO2005046635A3 Method for producing multiple emulsions that are stable in storage |
| 11/17/2005 | WO2005041883A3 Reduction of unintended use of transdermal devices |
| 11/17/2005 | WO2005000241A3 Compositons and methods for topical administration |
| 11/17/2005 | WO2005000222A3 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| 11/17/2005 | WO2004111185A3 Direct micro-patterning of lipid bilayers using uv light and selected uses thereof |
| 11/17/2005 | WO2004108114B1 Anti-fungal composition and a process for its manufacture |
| 11/17/2005 | WO2004096208A9 Composition for oral administration containing alkylene dioxybenzene derivative |
| 11/17/2005 | WO2001065911A9 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 11/17/2005 | US20050256548 System and method for monitoring power source longevity of an implantable medical device |
| 11/17/2005 | US20050256463 Cosmetic apparatus |
| 11/17/2005 | US20050256451 Vascular access port with needle detector |
| 11/17/2005 | US20050256430 Device and method for examining a body lumen |
| 11/17/2005 | US20050256255 Film coating |
| 11/17/2005 | US20050256211 Patient oxygenation using stabilized fluorocarbon emulsions |
| 11/17/2005 | US20050256194 Denaturants for sympathomimetic amine salts |
| 11/17/2005 | US20050256193 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| 11/17/2005 | US20050256188 Formulations of anthraquinone derivatives |
| 11/17/2005 | US20050256182 Formulations of anti-pain agents and methods of using the same |
| 11/17/2005 | US20050256152 Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations |
| 11/17/2005 | US20050256149 Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
| 11/17/2005 | US20050256117 Ophthalmic compositions for treating ocular hypertension |
| 11/17/2005 | US20050256088 condensates of an N-hydroxylamine and pyridoxal, pyridoxal phosphate, and heme-A, or a pharmaceutical salt thereof, and an excipient; prodrugs for releasing hydroxyamines for treating reverse age-related oxidative changes, delay senescence, and reverse mitochondrial decay; neuroprotective agents |
| 11/17/2005 | US20050256086 Fosinopril formulation |
| 11/17/2005 | US20050256063 Crystal forms of azithromycin |
| 11/17/2005 | US20050256062 A tablet of a crystalline form of azithromycin sesquihydrate or crystalline azithromycin monohydrate hemi-isopropanol solvate and a carrier or diluent; nuclear magnetic resonance spectrum analysis; bactericides; antiprotozoa agents; infections of humans, mammals, birds, fish; drug resistance |
| 11/17/2005 | US20050256060 Mono-and disaccharide derivatives |
| 11/17/2005 | US20050256045 Apparatus and method for transdermal delivery of parathyroid hormone agents |
| 11/17/2005 | US20050256038 Stable pharmaceutical compsition containing factor VIII |
| 11/17/2005 | US20050255165 Microspheres loaded with biologically active solid proteins; microspheres degrade over time and release biologically active VEGF |
| 11/17/2005 | US20050255164 Solid nano pharmaceutical formulation and preparation method thereof |
| 11/17/2005 | US20050255163 Co-grinding process for the preparation of a ternary composition |
| 11/17/2005 | US20050255162 Hydrophobic biomolecular structure |
| 11/17/2005 | US20050255161 Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water |
| 11/17/2005 | US20050255160 Polymide resin dermal composition |
| 11/17/2005 | US20050255159 comprising hydroxyapatite material made from mixture of calcium phosphate, calcium oxide and removable inorganic porogen such as iron oxide; biomimetics; biocompatible, biodegradable |
| 11/17/2005 | US20050255158 Combinations of HMG-COA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| 11/17/2005 | US20050255157 Sustained release, mucoadhesive vaginal pharmaceutical compositions |
| 11/17/2005 | US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 11/17/2005 | US20050255155 Modified release cilostazol compositions |
| 11/17/2005 | US20050255154 Method and composition for treating rhinitis |
| 11/17/2005 | US20050255153 Mixture of deprotonatable lipid, such as polyoxyethylene glycol or polyamide lipid with buffered aqueous solution of charged drug |
| 11/17/2005 | US20050255152 System for enhanced targeted delivery |
| 11/17/2005 | US20050255151 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 11/17/2005 | US20050255150 Wound treatment patch for alleviating pain |
| 11/17/2005 | US20050255149 Transdermal absorption preparation |
| 11/17/2005 | US20050255144 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies |
| 11/17/2005 | US20050255143 Method of use of carboxylated polysaccharides topically on the eyeball |
| 11/17/2005 | US20050255138 Active agent transport systems |